About Us: We are an IP house with patents in 3 Technology Areas:
Our Objective: To sell or license the IP for clinical development and commercialization.


Migraines and Seizures

NexGen's discovery of the common pathogenesis underlying seizures and migraines finally provides a coherent explanation for all of the observations and symptoms, a new understanding of the risk factors to be avoided, and most importantly allows for a novel pathogenesis based treatment approach in contrast to the symptom based treatment approaches used today. Existing drugs can be repurposed to rapidly provide relief to the 50 million seizure patients and 300 million migraine sufferers worldwide.

• Executive Summary (HTML) (PDF)

• Raloxifene and Seizures Opportunity (PDF)

• Full Specifications Data and Drawings (PDF)






Cancer

Cancer starts with a mutation(s) in growth control pathways in a single aberrant cell. That cell, and all of its progeny, are hard wired to relentlessly grow and divide. Accordingly, chemotherapy must kill every last cancer cell in order to be curative. The protocol criteria required to achieve curative outcome were defined several decades ago under principles of chemotherapy called the Skipper log cell kill model.

Stand alone S-Phase cytotoxic regimens in use today are not reliably curative because 2 inherent protocol deficiencies prevent them from being Skipper log cell kill model compliant.

Tumor Specific - Cell Cycle Synchronous Chemotherapy (TS - CCSC) protocols use existing drugs to target tumor specific mutations or characteristics in order to eliminate these deficiencies so that Skipper log cell kill model compliant regimens can be provided.

A slide deck on the TS-CCSC technology is provided below:


• TS - CCSC Slide Deck (PDF)


More detailed disclosures are provided in US Patent 7,507,704 (PDF) and in a detailed slide show on Cancer and Chemotherapy.





Targeted Transient Ribosomal Inhibition (TTRI)

TTRI silences expression of every protein involved in the underlying etiology and pathology of a disease condition in a target tissue mass, without adverse effect on normal cells. TTRI was tried for systemic use against cancer in the 1980’s. It is not suited for either systemic administration or use against cancer. However the wealth of human data obtained indicates it is a platform technology ideally suited for topical, inhalable, and transdermal administration for conditions where localized antiproliferative, anti-inflammatory, or antiviral activity is desired.

• Executive Summary (HTML) (PDF)

• Slide Show (PDF)

• Full Product, Clinical, and Patent Data (PDF)

• Comparison of TTRI to RNAi (HTML)





The Team


NexGen Biomedical, Inc., San Jose, CA Contact Info: Mark Zamoyski, e-mail to:mark@nexgen.biz


DISCLAIMER AND IMPORTANT NOTICE:The Compositions and Methods presented on this website are all in preclinical stages. They are based only on our understanding of the proposed underlying mechanisms of action and on any available coincidental corroborative empirical evidence, any of which may in fact turn out not to be correct, or may be prevented from functioning as envisioned because of other factors or mechanisms of action not contemplated or considered, or may even cause harm because of factors or mechanisms of action not anticipated. The process of obtaining FDA approvals has not been started in any of the areas disclosed on this website. The disclosures here are purely for scientific information exchange purposes, representing one scientific point of view, and are not intended to suggest, or be used for, any proposed medical treatments. NexGen Biomedical, Inc. is a California corporation established in 1999 .


© 2002 - 2014 Mark Zamoyski & NexGen Biomedical, Inc.